Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 37,919	$ 47,830	$ 124,492	$ 130,110
Operating expenses
Cost of revenue	19,346	14,907	55,937	41,320
Research and development	28,533	35,658	93,371	110,534
Sales and marketing	20,493	21,513	66,673	71,887
General and administrative	20,075	20,755	63,208	66,099
Amortization of intangible assets	428	428	1,270	1,270
Total operating expenses	88,875	93,261	280,459	291,110
Loss from operations	(50,956)	(45,431)	(155,967)	(161,000)
Interest and other income, net	4,282	765	10,918	1,454
Interest expense	(3,652)	(653)	(10,788)	(653)
Net loss	(50,326)	(45,319)	(155,837)	(160,199)
Add: Net loss attributable to noncontrolling interest	26	38	28	136
Net loss attributable to Adaptive Biotechnologies Corporation	$ (50,300)	$ (45,281)	$ (155,809)	$ (160,063)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	$ (0.35)	$ (0.32)	$ (1.08)	$ (1.12)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	144,704,868	142,928,654	144,208,940	142,334,342
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	$ (0.35)	$ (0.32)	$ (1.08)	$ (1.12)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	144,704,868	142,928,654	144,208,940	142,334,342